読み込み中
Minerva Neurosciences, Inc. functions as a biopharmaceutical firm in the clinical development stage, primarily dedicated to uncovering and bringing to market novel therapeutic options for disorders affecting the central nervous system. Its portfolio of experimental treatments notably features roluperidone, an investigational drug aimed at managing schizophrenia, alongside MIN-301, a soluble recombinant variant of the neuregulin-1b1 protein, which is being explored for its potential in treating Parkinson's disease and various other neurodegenerative conditions. The company has a contractual licensing agreement with Mitsubishi Tanabe Pharma Corporation, authorizing the worldwide development, distribution, and import of roluperidone, with the explicit exclusion of the Asian continent. Established in 2007, this organization initially operated as Cyrenaic Pharmaceuticals, Inc. before undergoing a name change to Minerva Neurosciences, Inc. in 2013. Its corporate headquarters are located in Waltham, Massachusetts.
前日終値
$3.18
−$0.04 · -1.24%
日中の時刻はETです。市場データは遅延する場合があります。
Minerva Neurosciences, Inc. functions as a biopharmaceutical firm in the clinical development stage, primarily dedicated to uncovering and bringing to market novel therapeutic options for disorders affecting the central nervous system. Its portfolio of experimental treatments notably features roluperidone, an investigational drug aimed at managing schizophrenia, alongside MIN-301, a soluble recombinant variant of the neuregulin-1b1 protein, which is being explored for its potential in treating Parkinson's disease and various other neurodegenerative conditions. The company has a contractual licensing agreement with Mitsubishi Tanabe Pharma Corporation, authorizing the worldwide development, distribution, and import of roluperidone, with the explicit exclusion of the Asian continent. Established in 2007, this organization initially operated as Cyrenaic Pharmaceuticals, Inc. before undergoing a name change to Minerva Neurosciences, Inc. in 2013. Its corporate headquarters are located in Waltham, Massachusetts.
日中レンジ
現在 $3.18
52週レンジ
現在 $3.18
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
中立
バリュエーション
60
適正価値
センチメント
44
まちまち
リスク
63
高リスク
モメンタム
41
中立
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Minerva Neurosciences, Inc. functions as a biopharmaceutical firm in the clinical development stage, primarily dedicated to uncovering and bringing to market novel therapeutic options for disorders affecting the central nervous system. Its portfolio of experimental treatments notably features roluperidone, an investigational drug aimed at managing schizophrenia, alongside MIN-301, a soluble recombinant variant of the neuregulin-1b1 protein, which is being explored for its potential in treating Parkinson's disease and various other neurodegenerative conditions. The company has a contractual licensing agreement with Mitsubishi Tanabe Pharma Corporation, authorizing the worldwide development, distribution, and import of roluperidone, with the explicit exclusion of the Asian continent. Established in 2007, this organization initially operated as Cyrenaic Pharmaceuticals, Inc. before undergoing a name change to Minerva Neurosciences, Inc. in 2013. Its corporate headquarters are located in Waltham, Massachusetts.
日中レンジ
現在 $3.18
52週レンジ
現在 $3.18
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 研究開発 | 575.95万 USD | 1189.86万 USD | 1270.53万 USD | 1464.91万 USD | 3203.89万 USD |
| 販売・一般管理 | 934.35万 USD | 994.98万 USD | 1041.43万 USD | 1058.22万 USD | 1332.67万 USD |
| 営業費用 | 1510.3万 USD | 2184.84万 USD | 2311.96万 USD | 2523.13万 USD | 4536.57万 USD |
| 受取利息 | 94.81万 USD | 127.2万 USD | 143.7万 USD | 55.69万 USD | 1.65万 USD |
| 支払利息 | — | 456.2万 USD | 828.3万 USD | 740.7万 USD | 632.7万 USD |
| 減価償却費と償却費 | 5442 USD | 2.25万 USD | 3.1万 USD | 8513 USD | 10.18万 USD |
| 営業利益 | −1510.3万 USD | −2184.84万 USD | −2311.96万 USD | −2523.13万 USD | −4536.57万 USD |
| 純利益 | −2.93億 USD | 143.89万 USD | −3000.54万 USD | −3210.87万 USD | −4990.6万 USD |
会社概要が更新されました 2026年10月11日.
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$10.00
上昇余地（214.47%）| 種別 | 発効日 | 詳細 | 基準日 | 支払日 |
|---|---|---|---|---|
株式分割 | 2022年6月21日 | 1:8 | — | — |
発効済み 2022年6月21日
1:8
この株式へのエクスポージャーを報告している上場投資信託です。
Vanguard Morningstar Total Stock Market ETFVTI641.34万0.00%2.3兆 USD0.03%$381.94+0.63%
iShares Russell 2000 ETFIWM271.99万0.00%787.4億 USD0.19%$278.94+0.49%
Vanguard Extended Market ETFVXF242.63万0.00%954億 USD0.05%$235+0.80%
Vanguard Russell 2000 ETFVTWO89.54万0.00%180億 USD0.06%$112.66+0.50%
iShares Russell 2000 Growth ETFIWO70.62万0.01%139.17億 USD0.24%$356.78+0.94%
iShares Micro-Cap ETFIWC36.91万0.03%13.17億 USD0.60%$183+0.11%
Vanguard Russell 2000 Growth ETFVTWG11.61万0.01%17億 USD0.06%$260.49+0.91%
Invesco NASDAQ Future Gen 200 ETFQQQS8.31万0.37%2275.83万 USD0.20%$42.145+1.39%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFVanguard Russell 2000 ETFVTWOiShares Russell 2000 Growth ETFIWOiShares Micro-Cap ETFIWCVanguard Russell 2000 Growth ETFVTWGInvesco NASDAQ Future Gen 200 ETFQQQSAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
